Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.
Yoav H. Messinger(Children’s Minnesota - St. Paul Hospital), Bruce Bostrom(Minnesota West Community & Technical College), Elizabeth A. Raetz(NYU Langone Health), Elena Eckroth(Children's Hospital of Los Angeles), Paul S. Gaynon(University of Southern California), Richard Sposto(Children's Hospital of Los Angeles), Raymond J. Hutchinson(Children's Hospital of Los Angeles), Steven G. DuBois(University of California, San Francisco), Julia Glade Bender(Columbia University Irving Medical Center), Jeannette van der Giessen(Children's Hospital of Los Angeles)
Cited by 5
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627